Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04372758
Other study ID # RECHMPL20_0245
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 30, 2020
Est. completion date January 1, 2021

Study information

Verified date May 2021
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Acute spontaneous Spinal Cord Infarctions (SCI) are an uncommon cause of myelopathy (5%), but their prognostic is heterogeneous and frequently severe. Positive diagnosis is difficult, one quarter of initial MRIs are normal. Differential diagnosis with other transverse myelopathy causes is a common issue. As in cerebral stroke, there are multiple causes and mechanisms in spontaneous SCI, often difficult to clearly establish. There are also clinical and radiological patterns, sometimes misleading, according to vascular territory and its expanse. Due to its scarcity and heterogeneity, improving knowledge and medical care remains difficult. Medical care is still badly codified in medical literature. Recently, diagnostic criteria have been proposed to better identify SCI, provide earlier care and homogenize future research. External validity and reproduction of these new criteria among acute myelopathies are still to be validated. While there is no established medical treatment in the initial care of spontaneous SCI, some case reports show successful treatment with IV thrombolysis. Given the severe prognosis, conventional treatment of strokes (thrombolysis, anticoagulant and antiplatelet), could be considered on an individual scale, in a specific protocol. A better knowledge of radio-clinical and security factors are necessary to support this approach. In order to respond to these difficulties, a retrospective cohort will allow us to better define epidemiological, clinico-radiological and prognostic features of spontaneous SCI. It lays the foundation of a possible prospective multicentric cohort, necessary for specific therapeutic studies.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 1, 2021
Est. primary completion date December 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Hospitalized patients in a medical ward in Montpellier and Nîmes University Hospitals with registered diagnosis of vascular myelopathy - And final diagnosis of spontaneous SCI after reviewing medical datas Exclusion criteria: - non ischemic myelopathies : compression, hematomyelia, spinal DAVF, intramedullary tumor, inflammatory, infectious or post-infectious myelitis, post-radiation myelopathy,…) - secondary SCI : SCI following an aortic, cardiac or rachidian surgery, extracorporeal circulation, post-hemodynamic shock - SCI without a cause

Study Design


Locations

Country Name City State
France Uhmontpellier Montpellier

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Montpellier Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary description of a recent spontaneous SCI cohort Number of patients hospitalized for spontaneous SCI in the last 10 years in Montpellier and Nîmes University Hospital 10 years
Primary description of a recent spontaneous SCI cohort description of patients diagnosed with spontaneous SCI 1 day
Secondary evaluation of JAMA 2019 diagnostic criteria in spontaneous SCI and other myelopathies evaluation of JAMA 2019 diagnostic criteria in spontaneous SCI and other myelopathies 1 day
Secondary analysis of relevant clinical and radiological criteria for positive diagnosis and prognosis analysis of relevant clinical and radiological criteria for positive diagnosis and prognosis 1 day
Secondary Description of clinico-radiological territories, etiology and physiopathology of spontaneous SCI, including application of fibrocartilaginous embolism criteria 2015 Description of clinico-radiological territories, etiology and physiopathology of spontaneous SCI, including application of fibrocartilaginous embolism criteria 2015 1 day
Secondary Retrospective evaluation of the potential candidates for IV thrombolysis Retrospective evaluation of the potential candidates for IV thrombolysis 1 day
Secondary Evaluation of relevant criteria in order to create a prospective multicentric cohort of spontaneous SCI. Evaluation of relevant criteria in order to create a prospective multicentric cohort of spontaneous SCI. 1 day